Department of Surgery, Kaunas University of Medicine, Eiveniu 2, 50009 Kaunas, Lithuania.
Medicina (Kaunas). 2010;46(5):299-304.
According to the current guidelines of proper TNM staging, 12 lymph nodes per specimen are crucial. This study assessed the role of preoperative radiochemotherapy on the number of lymph nodes detected in the tumor-bearing specimen.
Retrospective data of 138 patients who underwent surgery for stage II and III rectal cancer without preoperative radiochemotherapy during the period of 2004-2006 (control group) were compared with prospective data of 38 patients who received preoperative radiochemotherapy during the period of 2007-2008 (study group). The number of patients with metastatic lymph nodes, number of lymph nodes per specimen, number of metastatic lymph nodes per specimen, and the size of the tumor between the groups were compared.
Positive lymph nodes were detected in 88 (64%) patients in the control group as compared with 9 (21%) patients in the study group (P<0.05). The mean number of lymph nodes per specimen in the control group was 13.5, while in the study group, the mean number of lymph nodes per specimen was 6.29 (P<0.05). There was a significant difference in the mean number of metastatic lymph nodes per specimen between the groups (5.12 in the control group versus 2.11 in the study group; P<0.05). The mean size of the tumor was 4.37 cm in the control group and 2.45 cm in the study group (P<0.01).
Preoperative radiochemotherapy for advanced rectal cancer significantly decreased the number of lymph nodes detected in the tumor-bearing specimen. This also resulted in a significant decrease in the number of metastatic lymph nodes detected in the specimen, and fewer patients with stage III (N+) cancer were diagnosed. Preoperative radiochemotherapy could induce a significant downsizing and downstaging of advanced rectal cancer, but great care in operative and pathologic examination techniques must be taken to ensure appropriate staging.
根据当前的 TNM 分期指南,每个标本检测 12 个淋巴结至关重要。本研究评估了术前放化疗对肿瘤标本中检测到的淋巴结数量的影响。
回顾性分析 2004-2006 年期间未接受术前放化疗的 138 例 II 期和 III 期直肠癌患者(对照组)的资料,与 2007-2008 年期间接受术前放化疗的 38 例患者(研究组)前瞻性资料进行比较。比较两组患者的转移性淋巴结数量、每个标本的淋巴结数量、每个标本的转移性淋巴结数量和肿瘤大小。
对照组 88 例(64%)患者有阳性淋巴结,研究组 9 例(21%)患者有阳性淋巴结(P<0.05)。对照组每个标本的平均淋巴结数量为 13.5,而研究组为 6.29(P<0.05)。两组间每个标本的转移性淋巴结数量有显著差异(对照组 5.12,研究组 2.11;P<0.05)。对照组肿瘤的平均大小为 4.37cm,研究组为 2.45cm(P<0.01)。
术前放化疗可显著减少肿瘤标本中检测到的淋巴结数量。这也导致标本中检测到的转移性淋巴结数量显著减少,III 期(N+)癌症患者数量减少。术前放化疗可显著缩小和降期晚期直肠癌,但在手术和病理检查技术中必须非常小心,以确保适当的分期。